Clostridioides difficile 630 is an anaerobe, spore-forming, mesophilic human pathogen that was isolated from clinical isolate.
spore-forming rod-shaped anaerobe mesophilic human pathogen genome sequence| @ref 20215 |
Last LPSN update
2025-12-16 09:52:44 |
| Domain Bacillati |
| Phylum Bacillota |
| Class Clostridia |
| Order Peptostreptococcales |
| Family Peptostreptococcaceae |
| Genus Clostridioides |
| Species Clostridioides difficile |
| Full scientific name Clostridioides difficile (Hall and O'Toole 1935) Lawson et al. 2016 |
| Synonyms (3) |
| @ref | Name | Growth | Medium link | Composition | |
|---|---|---|---|---|---|
| 20942 | CHOPPED MEAT MEDIUM (DSMZ Medium 78) | Medium recipe at MediaDive  | Name: CHOPPED MEAT MEDIUM (DSMZ Medium 78) Composition: Ground beef 500.0 g/l Casitone 30.0 g/l Agar 15.0 g/l Ethanol 9.5 g/l (optional) K2HPO4 5.0 g/l Yeast extract 5.0 g/l L-Cysteine HCl 0.5 g/l Haemin 0.005 g/l (optional) Resazurin 0.001 g/l Vitamin K3 0.0005 g/l (optional) Vitamin K1 (optional) NaOH (optional) Distilled water | ||
| 20942 | FASTIDIOUS ANAEROBE AGAR (DSMZ Medium 1203) | Medium recipe at MediaDive | Name: FASTIDIOUS ANAEROBE AGAR (DSMZ Medium 1203) Composition: Horse blood 100.0 g/l Fastidious Anaerobe Agar 45.7 g/l Distilled water |
| @ref | Growth | Type | Temperature (°C) | Range | |
|---|---|---|---|---|---|
| 20942 | positive | growth | 37 | mesophilic |
| @ref | Chebi-ID | Metabolite | Utilization activity | Kind of utilization tested | |
|---|---|---|---|---|---|
| 68367 | 17634 ChEBI | D-glucose | + | builds acid from | from API 20A |
| 68367 | 16899 ChEBI | D-mannitol | + | builds acid from | from API 20A |
| 68367 | 16024 ChEBI | D-mannose | + | builds acid from | from API 20A |
| 68367 | 4853 ChEBI | esculin | + | hydrolysis | from API 20A |
| 68367 | 5291 ChEBI | gelatin | + | hydrolysis | from API 20A |
| 68367 | 17754 ChEBI | glycerol | - | builds acid from | from API 20A |
| 68367 | 30849 ChEBI | L-arabinose | - | builds acid from | from API 20A |
| 68380 | 29985 ChEBI | L-glutamate | - | degradation | from API rID32A |
| 68367 | 62345 ChEBI | L-rhamnose | - | builds acid from | from API 20A |
| 68367 | 17716 ChEBI | lactose | - | builds acid from | from API 20A |
| 68367 | 17306 ChEBI | maltose | - | builds acid from | from API 20A |
| 68367 | 6731 ChEBI | melezitose | + | builds acid from | from API 20A |
| 68380 | 17632 ChEBI | nitrate | - | reduction | from API rID32A |
| 68380 | 16634 ChEBI | raffinose | - | fermentation | from API rID32A |
| 68367 | 16634 ChEBI | raffinose | - | builds acid from | from API 20A |
| 68367 | 17992 ChEBI | sucrose | - | builds acid from | from API 20A |
| 68380 | 27897 ChEBI | tryptophan | - | energy source | from API rID32A |
| 68367 | 27897 ChEBI | tryptophan | - | energy source | from API 20A |
| 68380 | 16199 ChEBI | urea | - | hydrolysis | from API rID32A |
| 68367 | 16199 ChEBI | urea | - | hydrolysis | from API 20A |
| @ref | Value | Activity | Ec | |
|---|---|---|---|---|
| 68380 | alanine arylamidase | - | 3.4.11.2 | from API rID32A |
| 68380 | alkaline phosphatase | - | 3.1.3.1 | from API rID32A |
| 68380 | alpha-arabinosidase | - | 3.2.1.55 | from API rID32A |
| 68380 | alpha-fucosidase | - | 3.2.1.51 | from API rID32A |
| 68380 | alpha-galactosidase | - | 3.2.1.22 | from API rID32A |
| 68380 | alpha-glucosidase | - | 3.2.1.20 | from API rID32A |
| 68380 | beta-galactosidase | - | 3.2.1.23 | from API rID32A |
| 68380 | beta-Galactosidase 6-phosphate | - | from API rID32A | |
| 68367 | beta-glucosidase | + | 3.2.1.21 | from API 20A |
| 68380 | beta-glucuronidase | - | 3.2.1.31 | from API rID32A |
| 20942 | catalase | + | 1.11.1.6 | |
| 68367 | catalase | + | 1.11.1.6 | from API 20A |
| 20942 | cytochrome-c oxidase | - | 1.9.3.1 | |
| 68367 | gelatinase | + | from API 20A | |
| 68380 | glutamate decarboxylase | - | 4.1.1.15 | from API rID32A |
| 68380 | glutamyl-glutamate arylamidase | - | from API rID32A | |
| 68380 | glycin arylamidase | - | from API rID32A | |
| 68380 | histidine arylamidase | - | from API rID32A | |
| 68380 | L-arginine arylamidase | - | from API rID32A | |
| 68380 | leucyl glycin arylamidase | - | 3.4.11.1 | from API rID32A |
| 68380 | N-acetyl-beta-glucosaminidase | - | 3.2.1.52 | from API rID32A |
| 68380 | phenylalanine arylamidase | - | from API rID32A | |
| 68380 | proline-arylamidase | + | 3.4.11.5 | from API rID32A |
| 68380 | pyrrolidonyl arylamidase | - | 3.4.19.3 | from API rID32A |
| 68380 | serine arylamidase | - | from API rID32A | |
| 68380 | tryptophan deaminase | - | 4.1.99.1 | from API rID32A |
| 68380 | tyrosine arylamidase | - | from API rID32A | |
| 68380 | urease | - | 3.5.1.5 | from API rID32A |
| 68367 | urease | - | 3.5.1.5 | from API 20A |
| @ref | IND | URE | GLU | MAN | LAC | SAC | MAL | SAL | XYL | ARA | GEL | ESC | GLY | CEL | MNE | MLZ | RAF | SOR | RHA | TRE | CAT | Spores presentSPOR | GramGRAM | Morphology coccus="+" rod="-"COCC | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20942 | - | - | + | + | - | - | - | + | + | - | + | + | - | + | + | + | - | +/- | - | + | not determinedn.d. | not determinedn.d. | not determinedn.d. | not determinedn.d. | |
| 20942 | - | - | + | + | - | - | - | + | + | - | + | + | - | - | + | + | - | +/- | - | +/- | not determinedn.d. | not determinedn.d. | not determinedn.d. | not determinedn.d. | |
| 20942 | - | - | + | + | - | - | - | + | + | - | + | + | - | +/- | + | + | - | +/- | - | - | not determinedn.d. | not determinedn.d. | not determinedn.d. | not determinedn.d. | |
| 20942 | - | - | + | + | - | - | - | +/- | +/- | - | + | + | - | - | + | + | - | - | - | - | not determinedn.d. | not determinedn.d. | not determinedn.d. | not determinedn.d. | |
| 20942 | - | - | + | + | - | - | - | + | + | - | + | + | - | +/- | + | + | - | +/- | - | + | + | + | + | - | |
| 20942 | - | - | + | + | - | - | - | + | + | - | + | + | - | + | + | + | - | + | - | +/- | not determinedn.d. | not determinedn.d. | not determinedn.d. | not determinedn.d. |
| @ref | URE | ADH (Arg) | alpha GAL | beta GAL | beta-Galactosidase 6-phosphatebeta GP | alpha GLU | beta GLU | alpha ARA | beta GUR | beta-N-Acetyl-beta-glucosaminidasebeta NAG | MNE | RAF | GDC | alpha FUC | Reduction of nitrateNIT | IND | PAL | L-arginine arylamidaseArgA | ProA | LGA | Phenylalanine arylamidasePheA | Leucine arylamidaseLeuA | PyrA | Tyrosine arylamidaseTyrA | Alanine arylamidaseAlaA | Glycin arylamidaseGlyA | Histidine arylamidaseHisA | Glutamyl-glutamate arylamidaseGGA | Serine arylamidaseSerA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20942 | - | + | - | - | - | - | +/- | - | - | - | + | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | |
| 20942 | - | +/- | - | - | - | - | +/- | - | - | - | + | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | |
| 20942 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | |
| 20942 | - | - | - | - | - | - | +/- | - | - | - | - | - | - | - | - | - | - | - | + | - | - | + | - | - | - | - | - | - | - |
| @ref | Description | Assembly level | INSDC accession | BV-BRC accession | IMG accession | NCBI tax ID | Score | |
|---|---|---|---|---|---|---|---|---|
| 66792 | ASM93205v2 assembly for Clostridioides difficile 630 | complete | GCA_000932055   | 272563.120  | 2634166508  | 272563 | 98.9 | |
| 66792 | ASM920v2 assembly for Clostridioides difficile 630 | complete | GCA_000009205 | 272563.8 | 640069308 | 272563 | 98.73 | |
| 66792 | Clostridioides difficile 630 | complete | 2588253713 | 272563 | 81.54 | | ||
| 66792 | NCTC13307 assembly for Clostridioides difficile | complete | GCA_001457575 | 1496.877 | 2663762959 | 1496 | 23.58 | |
| Topic | Title | Authors | Journal | DOI | Year | |
|---|---|---|---|---|---|---|
| Genomic analysis of a novel ST11(PR34365) Clostridioides difficile strain isolated from the human fecal of a CDI patient in Guizhou, China. | Yang Y, Shu L, Ling P, Yang J, Shao R, Cheng Y, Luo S, Wei X, Guan Z, Chen Z, Liao J, Qi X, Cui G, Hong W. | Open Life Sci | 10.1515/biol-2025-1067 | 2025 | | |
| Metabolism | Formation of the pyruvoyl-dependent proline reductase Prd from Clostridioides difficile requires the maturation enzyme PrdH. | Behlendorf C, Diwo M, Neumann-Schaal M, Fuchs M, Korner D, Jansch L, Faber F, Blankenfeldt W. | PNAS Nexus | 10.1093/pnasnexus/pgae249 | 2024 | |
| The conserved noncoding RNA ModT coordinates growth and virulence in Clostridioides difficile. | Lence T, Sulzer J, Andress K, Gribling-Burrer AS, Lamm-Schmidt V, Barquist L, Smyth RP, Faber F. | PLoS Biol | 10.1371/journal.pbio.3002948 | 2024 | | |
| Proteotyping of Clostridioides difficile as Alternate Typing Method to Ribotyping Is Able to Distinguish the Ribotypes RT027 and RT176 From Other Ribotypes. | Emele MF, Joppe FM, Riedel T, Overmann J, Rupnik M, Cooper P, Kusumawati RL, Berger FK, Laukien F, Zimmermann O, Bohne W, Gross U, Bader O, Zautner AE. | Front Microbiol | 10.3389/fmicb.2019.02087 | 2019 | | |
| Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms. | Liu Y, Ma L, Cheng J, Su J. | Antimicrob Agents Chemother | 10.1128/aac.00221-23 | 2023 | | |
| Pathogenicity | Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis. | Brauer M, Herrmann J, Zuhlke D, Muller R, Riedel K, Sievers S. | Gut Pathog | 10.1186/s13099-021-00475-9 | 2022 | |
| Metabolism | An RNA-centric global view of Clostridioides difficile reveals broad activity of Hfq in a clinically important gram-positive bacterium. | Fuchs M, Lamm-Schmidt V, Sulzer J, Ponath F, Jenniches L, Kirk JA, Fagan RP, Barquist L, Vogel J, Faber F. | Proc Natl Acad Sci U S A | 10.1073/pnas.2103579118 | 2021 | |
| Genetics | Comparative genome and phenotypic analysis of three Clostridioides difficile strains isolated from a single patient provide insight into multiple infection of C. difficile. | Gross U, Brzuszkiewicz E, Gunka K, Starke J, Riedel T, Bunk B, Sproer C, Wetzel D, Poehlein A, Chibani C, Bohne W, Overmann J, Zimmermann O, Daniel R, Liesegang H. | BMC Genomics | 10.1186/s12864-017-4368-0 | 2018 | |
| Grad-seq identifies KhpB as a global RNA-binding protein in Clostridioides difficile that regulates toxin production. | Lamm-Schmidt V, Fuchs M, Sulzer J, Gerovac M, Hor J, Dersch P, Vogel J, Faber F. | Microlife | 10.1093/femsml/uqab004 | 2021 | | |
| Development of an in vitro Model of Human Gut Microbiota for Screening the Reciprocal Interactions With Antibiotics, Drugs, and Xenobiotics. | El Houari A, Ecale F, Mercier A, Crapart S, Laparre J, Soulard B, Ramnath M, Berjeaud JM, Rodier MH, Crepin A. | Front Microbiol | 10.3389/fmicb.2022.828359 | 2022 | | |
| Metabolism | Using gas mixtures of CO, CO2 and H2 as microbial substrates: the do's and don'ts of successful technology transfer from laboratory to production scale. | Takors R, Kopf M, Mampel J, Bluemke W, Blombach B, Eikmanns B, Bengelsdorf FR, Weuster-Botz D, Durre P. | Microb Biotechnol | 10.1111/1751-7915.13270 | 2018 | |
| Pig-L mediates virulence, biofilm formation, and oxidative stress tolerance in Clostridioides difficile. | Cheng Y, Hu H, Huang T, Luo X, Chen F, Shi P, Ma W, Lu Y, Lan S, Cui G, Qi X, Liu YJ, Hong W. | Front Microbiol | 10.3389/fmicb.2025.1691769 | 2025 | | |
| Differences in virulence and drug resistance between Clostridioides difficile ST37 and ST1 isolates. | Ouyang Z, Yang J, Zhang H, Zhao M, Yang H, Zhao J, Yang Y, Qiang C, Li Z, Qin P, Wang W, Niu Y, Zhao J. | Virulence | 10.1080/21505594.2025.2502554 | 2025 | | |
| Genetics | Host origin of microbiota drives functional recovery and Clostridioides difficile clearance in mice. | Millard SA, Vendrov KC, Young VB, Seekatz AM. | mBio | 10.1128/mbio.01108-25 | 2025 | |
| Pathogenicity | Mouse monoclonal antibodies against Clostridioides difficile toxins TcdA and TcdB target diverse epitopes for neutralization. | Kroh HK, Jensen JL, Wellnitz S, Park JJ, Esadze A, Huynh KW, Ammirati M, Han S, Anderson AS, Lacy DB, Gribenko A. | Infect Immun | 10.1128/iai.00139-25 | 2025 | |
| Antimicrobial Activity of Tannic Acid In Vitro and Its Protective Effect on Mice against Clostridioides difficile. | Wang W, Cao J, Yang J, Niu X, Liu X, Zhai Y, Qiang C, Niu Y, Li Z, Dong N, Wen B, Ouyang Z, Zhang Y, Li J, Zhao M, Zhao J. | Microbiol Spectr | 10.1128/spectrum.02618-22 | 2023 | | |
| Identification of an Antimicrobial Peptide from the Venom of the Trinidad Thick-Tailed Scorpion Tityus trinitatis with Potent Activity against ESKAPE Pathogens and Clostridioides difficile. | Mechkarska M, Cunning TS, Taggart MG, Ternan NG, Leprince J, Coquet L, Jouenne T, Tena-Garces J, Calvete JJ, Conlon JM. | Antibiotics (Basel) | 10.3390/antibiotics12091404 | 2023 | | |
| Enzymology | CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against Clostridioides difficile Infection and Recurrence in Mouse and Hamster Infection Models. | Hu X, Dong R, Huang S, Zeng Y, Zhan W, Gao X, Tian D, Peng J, Xu J, Wang T, Zhang Y, Wang X, Zhang X, Liu J, Guang B, Yang T. | Antimicrob Agents Chemother | 10.1128/aac.01704-22 | 2023 | |
| Metabolism | Butyrate enhances Clostridioides difficile sporulation in vitro. | Baldassare MA, Bhattacharjee D, Coles JD, Nelson S, McCollum CA, Seekatz AM. | J Bacteriol | 10.1128/jb.00138-23 | 2023 | |
| Genetics | Esculin hydrolysis negative and TcdA-only producing strains of Clostridium (Clostridioides) difficile from the environment in Western Australia. | Shivaperumal N, Knight DR, Imwattana K, Androga GO, Chang BJ, Riley TV. | J Appl Microbiol | 10.1111/jam.15500 | 2022 | |
| Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection. | Rubio-Mendoza D, Martinez-Melendez A, Maldonado-Garza HJ, Cordova-Fletes C, Garza-Gonzalez E. | Microorganisms | 10.3390/microorganisms11102525 | 2023 | | |
| Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance. | Herzog MK, Cazzaniga M, Peters A, Shayya N, Beldi L, Hapfelmeier S, Heimesaat MM, Bereswill S, Frankel G, Gahan CGM, Hardt WD. | Gut Microbes | 10.1080/19490976.2023.2172667 | 2023 | | |
| Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile. | Budi N, Godfrey JJ, Safdar N, Shukla SK, Rose WE. | Antimicrob Agents Chemother | 10.1128/aac.01431-20 | 2023 | | |
| Bioinformatics-driven discovery of novel Clostridioides difficile lysins and experimental comparison with highly active benchmarks. | Furlon JM, Mitchell SJ, Bailey-Kellogg C, Griswold KE. | Biotechnol Bioeng | 10.1002/bit.27759 | 2021 | | |
| Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. | Ma Z, He S, Yuan Y, Zhuang Z, Liu Y, Wang H, Chen J, Xu X, Ding C, Molodtsov V, Lin W, Robertson GT, Weiss WJ, Pulse M, Nguyen P, Duncan L, Doyle T, Ebright RH, Lynch AS. | J Med Chem | 10.1021/acs.jmedchem.1c02045 | 2022 | | |
| Genetic diversity and epidemiology of accessory gene regulator loci in Clostridioides difficile. | Okada Y, Okugawa S, Ikeda M, Kobayashi T, Saito R, Higurashi Y, Moriya K. | Access Microbiol | 10.1099/acmi.0.000134 | 2020 | | |
| Metabolism | Aging Dampens the Intestinal Innate Immune Response during Severe Clostridioides difficile Infection and Is Associated with Altered Cytokine Levels and Granulocyte Mobilization. | Abernathy-Close L, Dieterle MG, Vendrov KC, Bergin IL, Rao K, Young VB. | Infect Immun | 10.1128/iai.00960-19 | 2020 | |
| Protection from Lethal Clostridioides difficile Infection via Intraspecies Competition for Cogerminant. | Leslie JL, Jenior ML, Vendrov KC, Standke AK, Barron MR, O'Brien TJ, Unverdorben L, Thaprawat P, Bergin IL, Schloss PD, Young VB. | mBio | 10.1128/mbio.00522-21 | 2021 | | |
| A common protocol for the simultaneous processing of multiple clinically relevant bacterial species for whole genome sequencing. | Raven KE, Girgis ST, Akram A, Blane B, Leek D, Brown N, Peacock SJ. | Sci Rep | 10.1038/s41598-020-80031-8 | 2021 | | |
| Phylogeny | Identification and Characterization of Clostridium difficile Sequence Type 37 Genotype by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. | Li R, Xiao D, Yang J, Sun S, Kaplan S, Li Z, Niu Y, Qiang C, Zhai Y, Wang X, Zhao X, Zhao B, Welker M, Pincus DH, Jin D, Jin D, Kamboj M, Zheng G, Zhang G, Zhang J, Tang YW, Zhao J. | J Clin Microbiol | 10.1128/jcm.01990-17 | 2018 | |
| Metabolism | Clostridium difficile is an autotrophic bacterial pathogen. | Kopke M, Straub M, Durre P. | PLoS One | 10.1371/journal.pone.0062157 | 2013 | |
| Metabolism | Bile salt inhibition of host cell damage by Clostridium difficile toxins. | Darkoh C, Brown EL, Kaplan HB, DuPont HL. | PLoS One | 10.1371/journal.pone.0079631 | 2013 | |
| A Deep Learning Approach to Antibiotic Discovery. | Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackermann Z, Tran VM, Chiappino-Pepe A, Badran AH, Andrews IW, Chory EJ, Church GM, Brown ED, Jaakkola TS, Barzilay R, Collins JJ. | Cell | 10.1016/j.cell.2020.01.021 | 2020 | | |
| Pathogenicity | New role for human alpha-defensin 5 in the fight against hypervirulent Clostridium difficile strains. | Furci L, Baldan R, Bianchini V, Trovato A, Ossi C, Cichero P, Cirillo DM. | Infect Immun | 10.1128/iai.02955-14 | 2015 | |
| The Gut Microbiota Is Associated with Clearance of Clostridium difficile Infection Independent of Adaptive Immunity. | Leslie JL, Vendrov KC, Jenior ML, Young VB. | mSphere | 10.1128/mspheredirect.00698-18 | 2019 | | |
| Pathogenicity | Metronidazole-triazole conjugates: activity against Clostridium difficile and parasites. | Jarrad AM, Karoli T, Debnath A, Tay CY, Huang JX, Kaeslin G, Elliott AG, Miyamoto Y, Ramu S, Kavanagh AM, Zuegg J, Eckmann L, Blaskovich MA, Cooper MA. | Eur J Med Chem | 10.1016/j.ejmech.2015.06.019 | 2015 | |
| Indomethacin increases severity of Clostridium difficile infection in mouse model. | Munoz-Miralles J, Trindade BC, Castro-Cordova P, Bergin IL, Kirk LA, Gil F, Aronoff DM, Paredes-Sabja D. | Future Microbiol | 10.2217/fmb-2017-0311 | 2018 | | |
| Enzymology | Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. | Darkoh C, Dupont HL, Kaplan HB. | J Clin Microbiol | 10.1128/jcm.01033-11 | 2011 | |
| Pathogenicity | The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI. | Garland M, Hryckowian AJ, Tholen M, Bender KO, Van Treuren WW, Loscher S, Sonnenburg JL, Bogyo M. | Cell Rep Med | 10.1016/j.xcrm.2020.100005 | 2020 | |
| Pathogenicity | Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. | Gooyit M, Janda KD. | Sci Rep | 10.1038/srep33642 | 2016 | |
| Pathogenicity | In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. | Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ. | J Antimicrob Chemother | 10.1093/jac/dkv006 | 2015 | |
| Pathogenicity | Effect of the Synthetic Bile Salt Analog CamSA on the Hamster Model of Clostridium difficile Infection. | Howerton A, Seymour CO, Murugapiran SK, Liao Z, Phan JR, Estrada A, Wagner AJ, Mefferd CC, Hedlund BP, Abel-Santos E. | Antimicrob Agents Chemother | 10.1128/aac.02251-17 | 2018 | |
| Metabolism | Clostridium difficile-induced colitis in mice is independent of leukotrienes. | Trindade BC, Theriot CM, Leslie JL, Carlson PE, Bergin IL, Peters-Golden M, Young VB, Aronoff DM. | Anaerobe | 10.1016/j.anaerobe.2014.09.006 | 2014 | |
| Metabolism | Wall Teichoic Acids Are Involved in the Medium-Induced Loss of Function of the Autolysin CD11 against Clostridium difficile. | Wu X, Paskaleva EE, Mehta KK, Dordick JS, Kane RS. | Sci Rep | 10.1038/srep35616 | 2016 | |
| Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. | Seekatz AM, Theriot CM, Molloy CT, Wozniak KL, Bergin IL, Young VB. | Infect Immun | 10.1128/iai.00459-15 | 2015 | | |
| A novel subtyping assay for detection of Clostridium difficile virulence genes. | Angione SL, Sarma AA, Novikov A, Seward L, Fieber JH, Mermel LA, Tripathi A. | J Mol Diagn | 10.1016/j.jmoldx.2013.11.006 | 2014 | | |
| Metabolism | Diverse Energy-Conserving Pathways in Clostridium difficile: Growth in the Absence of Amino Acid Stickland Acceptors and the Role of the Wood-Ljungdahl Pathway. | Gencic S, Grahame DA. | J Bacteriol | 10.1128/jb.00233-20 | 2020 | |
| Metabolism | Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection. | Buonomo EL, Cowardin CA, Wilson MG, Saleh MM, Pramoonjago P, Petri WA. | Cell Rep | 10.1016/j.celrep.2016.06.007 | 2016 | |
| Pathogenicity | Effects of tigecycline and vancomycin administration on established Clostridium difficile infection. | Theriot CM, Schumacher CA, Bassis CM, Seekatz AM, Young VB. | Antimicrob Agents Chemother | 10.1128/aac.04296-14 | 2015 | |
| A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. | Takahashi MK, Tan X, Dy AJ, Braff D, Akana RT, Furuta Y, Donghia N, Ananthakrishnan A, Collins JJ. | Nat Commun | 10.1038/s41467-018-05864-4 | 2018 | | |
| Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile. | Darkoh C, Odo C, DuPont HL. | mBio | 10.1128/mbio.01237-16 | 2016 | | |
| Metabolism | Toxin synthesis by Clostridium difficile is regulated through quorum signaling. | Darkoh C, DuPont HL, Norris SJ, Kaplan HB. | mBio | 10.1128/mbio.02569-14 | 2015 | |
| Immunogenicity and protective efficacy of Clostridium difficile spore proteins. | Ghose C, Eugenis I, Edwards AN, Sun X, McBride SM, Ho DD. | Anaerobe | 10.1016/j.anaerobe.2015.12.001 | 2016 | | |
| Fate of ingested Clostridium difficile spores in mice. | Howerton A, Patra M, Abel-Santos E. | PLoS One | 10.1371/journal.pone.0072620 | 2013 | | |
| Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. | Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. | Gut Microbes | 10.4161/gmic.19142 | 2011 | | |
| Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. | Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB. | Infect Immun | 10.1128/iai.00647-12 | 2012 | | |
| Pathogenicity | Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. | Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS. | Antimicrob Agents Chemother | 10.1128/aac.00360-12 | 2012 | |
| Pathogenicity | Mapping interactions between germinants and Clostridium difficile spores. | Howerton A, Ramirez N, Abel-Santos E. | J Bacteriol | 10.1128/jb.00980-10 | 2011 | |
| Metabolism | Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. | Darkoh C, Kaplan HB, Dupont HL. | J Clin Microbiol | 10.1128/jcm.00037-11 | 2011 | |
| Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens. | Venhorst J, van der Vossen JMBM, Agamennone V. | Front Microbiol | 10.3389/fmicb.2022.891790 | 2022 | | |
| Enzymology | A low complexity rapid molecular method for detection of Clostridium difficile in stool. | McElgunn CJ, Pereira CR, Parham NJ, Smythe JE, Wigglesworth MJ, Smielewska A, Parmar SA, Gandelman OA, Brown NM, Tisi LC, Curran MD. | PLoS One | 10.1371/journal.pone.0083808 | 2014 | |
| Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin. | Warn P, Thommes P, Sattar A, Corbett D, Flattery A, Zhang Z, Black T, Hernandez LD, Therien AG. | Antimicrob Agents Chemother | 10.1128/aac.00974-16 | 2016 | | |
| Enzymology | Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. | Mayer MJ, Narbad A, Gasson MJ. | J Bacteriol | 10.1128/jb.00686-08 | 2008 | |
| Cultivation | Generation of a fully erythromycin-sensitive strain of Clostridioides difficile using a novel CRISPR-Cas9 genome editing system. | Ingle P, Groothuis D, Rowe P, Huang H, Cockayne A, Kuehne SA, Jiang W, Gu Y, Humphreys CM, Minton NP | Sci Rep | 10.1038/s41598-019-44458-y | 2019 | |
| Genetics | Manual curation and reannotation of the genomes of Clostridium difficile 630Deltaerm and C. difficile 630. | Dannheim H, Riedel T, Neumann-Schaal M, Bunk B, Schober I, Sproer C, Chibani CM, Gronow S, Liesegang H, Overmann J, Schomburg D | J Med Microbiol | 10.1099/jmm.0.000427 | 2017 | |
| In vitro Study of Lactobacillus paracasei CNCM I-1518 in Healthy and Clostridioides difficile Colonized Elderly Gut Microbiota. | Fehlbaum S, Chassard C, Schwab C, Voolaid M, Fourmestraux C, Derrien M, Lacroix C | Front Nutr | 10.3389/fnut.2019.00184 | 2019 | |
How to citeIf you want to cite this particular strain cite the following doi:
https://doi.org/10.13145/bacdive23853.20251217.10
When using BacDive for research please cite the following paper
BacDive in 2025: the core database for prokaryotic strain data
License